Table 2

 Incremental effects, costs, and cost effectiveness of the new strategy for detection and surveillance of CRC patients and relatives compared with the current strategy (detected for carrying a deleterious mutation that predisposes for HNPCC)

CRC patientsChildren and siblings
Overall incremental costs per life year gained: €2184.
Extra HNPCC mutation carriers detected (%)1.91
Incremental screening costs (€)1419
Incremental costs/mutation carrier detected (€)7330950
Incremental surveillance costs (€)19271675
Life years gained2.53
Incremental costs per life year gained (€)3801855